Modelos animales en anfibios

Un modelo animal es aquel que emplea animales de especies distintas a la humana, seleccionados por sus características específicas, para ser utilizados en investigación o docencia. En el diseño de los mismos las claves son la elección de la especie animal y la viabilidad de extrapolación de los datos obtenidos a la especie en que se vayan a aplicar los resultados obtenidos. En este trabajo se revisan los aspectos anatómicos, fisiológicos y ecológicos que han convertido a algunas especies de anfibios en unas de las más utilizadas como modelos animales en experimentación dentro de campos diversos (fisiología, toxicología): facilidad de mantenimiento en cautividad, excelente adaptabilidad a diversos hábitats, elevada prolificidad, capacidad de regeneración de tejido y gran sensibilidad de los individuos adultos y de sus embriones a los cambios del medio ambiente. Así mismo, se hace una revisión de las especies más utilizadas por campos de investigación.An animal model is a non-human animal useful for research and teaching because it has specific characteristics that resemble a human or superior animal. In the design of those animal models, the keys are the election of the correct species and the viability to extrapolate the data obtained to the species in which these are going to be used. In this work the anatomic, physiologic and ecological aspects that turn some of the amphibian species in the most employed animal models in investigation are reviewed. These are: easy breeding, tolerance to diverse habitats, high prolificity, phylogenetic and ecological diversity, tissue regeneration capability, unique ability to undergo metamorphosis, high sensitivity to climatic and habitat changes. The most important amphibian models used in research are reviewed in this article

How to support mobility students to gain soft-competences: Knowledge, Skills and Attitudes

Students participating in mobility experiences have a great learning opportunity, but in many cases they hardly realise about the soft-competences they developed during mobility. In this context, the supporting role of universities is key for students to make the most of their mobility and be able to communicate their learning outcomes. This study analyses the support services that students receive for the development and acknolwledgement of mobility soft comptencies (related with the three dimensiones: knowledge, skills and attitudes or KSAs) in order to define the university strategy in this field. Results show two types of support for outgoing and incoming students: (i) passive initiatives based on delivering relevant information for the mobility period to students; and (ii) active initiatives based on training activities and activities for student integration in the host university/city/culture. No support initiatives on mobility related KSAs for returned students or academic staff have been identified.De La Torre, EM.; Casani, F.; Pérez Encinas, A.; Rodríguez Pomeda, J. (2020). How to support mobility students to gain soft-competences: Knowledge, Skills and Attitudes. En 6th International Conference on Higher Education Advances (HEAd'20). Editorial Universitat Politècnica de València. (30-05-2020):1279-1287. https://doi.org/10.4995/HEAd20.2020.11248OCS1279128730-05-202

Estudio del veneno de serpientes: tipos y tratamientos

Los venenos de las serpientes constituyen una mezcla de más de 20 polipéptidos distintos, donde se incluyen enzimas, toxinas y pequeños péptidos. Su inoculación mediante mordedura puede producir diversos tipos de intoxicación, cuyos síntomas se resumen en dos cuadros patológicos: neurotóxico y hemotóxico. La gravedad del proceso depende de factores propios del veneno, de la propia mordedura y de la presa y las lesiones, en algunos casos, pueden ser permanentes. El protocolo de actuación en caso de envenenamiento se basa en tres puntos: actuaciones de primeros auxilios (extracción del veneno, corte del riego linfático), tratamiento etiológico (administración de sueros antiofídicos) y tratamiento sintomático (farmacológico o quirúrgico).Snake venoms are mixtures of more than 20 different polypeptides where enzymes, toxins and small peptides are included. Snakes inoculate their venom during the bite and then different envenomations can occur. The symptoms are described by two pathological processes: neurotoxic and haemotoxic. The gravity of the intoxication depends on some venom, bite and catch factors and sometimes the injuries can be everlasting. When a human being is bitten by a venomous snake, three steps must be taken: first aid (venom extraction and lymphatic circulation cut) and etiological (specific anti-venom serum administration) and symptomatic (pharmacological or surgical) treatment

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Objective The obesity/overweight may have an influence on APL outcomes. Methods This is the biggest multicentre analysis on 1320 APL patients treated with AIDA-induction and risk-adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (= 30 kg/m(2)) according to the World Health Organization (WHO) criteria. Results and conclusions Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI >= 25 vs BMI = 25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value (P = .46). There was no higher incidence of differentiation syndrome with BMI >= 25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy-free regimens remains to be established

Efficient ultraviolet-light energy dissipation by an aromatic ketone

Experimental evidence on the efficiency of 2,2'4,4'-tetramethoxybenzil for UV-light energy dissipation is provided. This non-phenolic aromatic ketone has a low energy triplet which quickly decays to the ketone ground state, thus avoiding the generation of undesirable reactive species.El Moncef, Abdelkarim, [email protected] ; Cuquerella Alabort, Maria Consuelo, [email protected] ; Zaballos Garcia, Elena, [email protected] ; Ramirez de Arellano Sanchez, Maria del Carmen, [email protected] ; Stiriba, Salah Eddine, [email protected] ; Perez Prieto, Julia, [email protected]

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

The role of decentralized assessment of measurable residual disease (MRD) for risk stratification in acute myeloid leukemia (AML) remains largely unknown, and so it does which methodological aspects are critical to empower the evaluation of MRD with prognostic significance, particularly if using multiparameter flow cytometry (MFC). We analyzed 1076 AML patients in first remission after induction chemotherapy, in whom MRD was evaluated by MFC in local laboratories of 60 Hospitals participating in the PETHEMA registry. We also conducted a survey on technical aspects of MRD testing to determine the impact of methodological heterogeneity in the prognostic value of MFC. Our results confirmed the recommended cutoff of 0.1% to discriminate patients with significantly different cumulative-incidence of relapse (-CIR- HR:0.71, P < 0.001) and overall survival (HR: 0.73, P = 0.001), but uncovered the limited prognostic value of MFC based MRD in multivariate and recursive partitioning models including other clinical, genetic and treatment related factors. Virtually all aspects related with methodological, interpretation, and reporting of MFC based MRD testing impacted in its ability to discriminate patients with different CIR. Thus, this study demonstrated that “real-world” assessment of MRD using MFC is prognostic in patients at first remission, and urges greater standardization for improved risk-stratification toward clinical decisions in AML.This study was supported by the Centro de Investigación Biomédica en Red – Área de Oncología - del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369, CB16/12/00233, CB16/12/00284 and CB16/12/00400), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS No. PI16/01661, PI16/00517 and PI18/01946), Gerencia Regional de Salud de CyL (GRS 1346/A/16) and the Plan de Investigación de la Universidad de Navarra (PIUNA 2014-18). This study was supported internationally by the Cancer Research UK, FCAECC and AIRC under the Accelerator Award Program EDITOR

Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis : Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis Transplant Scoring System (MTSS) and identify risk factors for survival in a multicenter series of 197 patients with MF undergoing allo-HCT. After a median follow-up of 3.1 years, 47% of patients had died, and the estimated 5-year survival rate was 51%. Projected 5-year risk of nonrelapse mortality and relapse incidence was 30% and 20%, respectively. Factors independently associated with increased mortality were a hematopoietic cell transplantation-specific comorbidity index (HCT-CI) ≥3 and receiving a graft from an HLA-mismatched unrelated donor or cord blood, whereas post-transplant cyclophosphamide (PT-Cy) was associated with improved survival. Donor type was the only parameter included in the MTSS model with independent prognostic value for survival. According to the MTSS, 3-year survival was 62%, 66%, 37%, and 17% for low-, intermediate-, high-, and very high-risk groups, respectively. By pooling together the low- and intermediate-risk groups, as well as the high- and very high-risk groups, we pinpointed 2 categories: standard risk and high risk (25% of the series). Three-year survival was 62% in standard-risk and 25% in high-risk categories (P <.001). We derived a risk score based on the 3 independent risk factors for survival in our series (donor type, HCT-CI, and PT-Cy). The corresponding 5-year survival for the low-, intermediate-, and high-risk categories was 79%, 55%, and 32%, respectively (P <.001). In conclusion, the MTSS model failed to clearly delineate 4 prognostic groups in our series but may still be useful to identify a subset of patients with poor outcome. We provide a simple prognostic scoring system for risk/benefit considerations before transplantation in patients with MF

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

Although survival of elderly myeloma patients has significantly improved there is still a subset of patients who, despite being fit and achieving optimal responses, will die within 2 years of diagnosis due to myeloma progression. The objective of this study was to define a scoring prognostic index to identify this group of patients. We have evaluated the outcome of 490 newly diagnosed elderly myeloma patients included in two Spanish trials (GEM2005-GEM2010). Sixty-eight patients (13.8%) died within 2 years of diagnosis (early deaths) due to myeloma progression. Our study shows that the use of simple scoring model based on 4 widely available markers (elevated LDH, ISS 3, high risk CA or >75 years) can contribute to identify up-front these patients. Moreover, unsustained response (<6 months duration) emerged as one important predictor of early myeloma-related mortality associated with a significant increase in the risk of death related to myeloma progression. The identification of these patients at high risk of early death is relevant for innovative trials aiming to maintain the depth of first response, since many of them will not receive subsequent lines of therapy.This study was supported by the Cooperative Research Thematic Networkgrants RD12/0036/0058 and RD12/0036/0046 of the Redde Cancer (Cancer Network of Excellence); Instituto deSalud Carlos III, Spain, Instituto de Salud Carlos III/SubdirecciónGeneral de Investigación Sanitaria part-financedby the European Regional Development Fund (FIS: PI12/01761; PI12/02311; PI13/01469; PI14/01867, G03/136;Sara Borrell: CD13/00340); Asociación Española Contra el Cáncer (GCB120981SAN) and FEDER

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or without clarithromycin until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). With a median follow-up of 19 months (range, 0-54), no significant differences in the median PFS were observed between the two arms (C-Rd 23 months, Rd 29 months; HR 0.783, p = 0.14), despite a higher rate of complete response (CR) or better in the C-Rd group (22.6% vs 14.4%, p = 0.048). The most common G3-4 adverse events were neutropenia [12% vs 19%] and infections [30% vs 25%], similar between the two arms; however, the percentage of toxic deaths was higher in the C-Rd group (36/50 [72%] vs 22/40 [55%], p = 0.09). The addition of clarithromycin to Rd in untreated transplant ineligible MM patients does not improve PFS despite increasing the ?CR rate due to the higher number of toxic deaths in the C-Rd arm. Side effects related to overexposure to steroids due to its delayed clearance induced by clarithromycin in this elderly population could explain these results. The trial was registered in clinicaltrials.gov with the name GEM-CLARIDEX: Ld vs BiRd and with the following identifier NCT02575144. The full trial protocol can be accessed from ClinicalTrials.gov. This study received financial support from BMS/Celgene